Novo Nordisk

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 54,400 people in 80 countries and markets its products in around 170 countries. For more information visit novonordisk.com.

Our US Research & Development hub, located in the Greater Boston area, brings together the best talent to drive life science innovation. Located in Lexington, Watertown and Cambridge, our teams reflect the full scope of R&D, from early research through late-stage clinical development. We are building for the future by creating a distinct R&D community based on collaboration, partnerships, and cutting-edge research across multiple modalities and therapeutic areas. We recognize that improving human health starts here and that patients rely on us. By combining the speed and agility of biotech with the quality, resources, and stability of a large pharmaceutical company, our US R&D hub will benefit from the best of both worlds to develop new medicines that meet the needs of patients.

Novo Nordisk is its people. We rely on the diversity of perspectives from colleagues all around the world. Our forward thinking, supported by careers that are as dynamic as we are, makes Novo Nordisk a great place to be and be from. This is your moment. Here we don’t stand still, we never give up – we make an impact. We’re trusted to have the courage. Together, we make it happen.

75 Hayden Avenue
Lexington, MA 02421

Tel: 617-612-6200

Visit website

NEWS

Policy

Lilly and Novo Nordisk Question FDA’s Draft Guidance on Insulin Biosimilars

In November 2019, the U.S. Food and Drug Administration (FDA) released new draft guidance that would help generic drug companies bring biosimilars to insulin to the market more quickly. And now there are reports that two of the three primary biopharma companies that sell insulin in the U.S. are trying to change that draft guidance.

February 12, 2020

3 min read

Mark Terry

Pharm Country

Novo Nordisk launches ESPEROCT® in the U.S. for the treatment of people with hemophilia A

When used by adults every four days, ESPEROCT® can help reduce the frequency of bleeding with less frequent dosing

February 10, 2020

5 min read

Business

Biotech Q4 Earnings Synopsis: Major Restructuring and Overall Growth Are Themes

It was a busy week for biotech quarterly and annual reports. Here’s a look at some of the top stories including Bristol-Myers Squibb, AbbVie, GSK, Merck and more.

February 7, 2020

6 min read

Mark Terry

FDA

Novo Nordisk’s Ozempic Wins Approval for Reducing Cardiovascular Events in Diabetes Patients

For patients with diabetes, the new indication could become a key for survival as there is a well-established link between cardiovascular disease and type 2 diabetes.

January 17, 2020

2 min read

Alex Keown

Deals

M&A for 2019 was Big; Will 2020 Be Even Bigger?

Consulting firm EY released its annual report on mergers and acquisitions (M&A) to coincide with the JP Morgan Healthcare conference this week. For 2019, EY indicates there were $357 billion in life science deals, an “all-time record,” surpassing the previous high in 2014.

January 13, 2020

4 min read

Mark Terry

rBIO Chief Product Officer Jonas Moses/courtesy rB

FDA

Novo Nordisk Wins FDA Approval for Mealtime Insulin Treatment for Children

The company said Fiasp is the “first and only fast-acting mealtime insulin injection that does not have a pre-meal dosing recommendation.”

January 7, 2020

2 min read

Alex Keown

Novo Nordisk Launches $99 Insulin Program

In the My$99Insulin Program, patients can buy up to three vials or two packs of FlexPen/FlexTouch/PenFill pens of any combination of Novo Nordisk insulins for $99.

January 2, 2020

3 min read

Mark Terry

With Scrutiny of Insulin Drugmakers, Is Novo Nordisk a Buy for 2020 Investors?

With a new year upon us, some analysts are already picking potential winners in the market for 2020. One of those companies could be Denmark-based Novo Nordisk.

December 31, 2019

2 min read

Alex Keown

FDA

Most Important Drugs Over the Past 10 Years

Looking back over the past year and even decade, STAT News takes a look back at the best drugs approved over the past 10 years in its weekly Readout podcast.

December 20, 2019

3 min read

Alex Keown

JOBS